Welcome to our dedicated page for Helix Acqsn II news (Ticker: HLXB), a resource for investors and traders seeking the latest updates and insights on Helix Acqsn II stock.
Helix Acquisition Corp II (HLXB) provides investors with critical updates through this dedicated news hub for this Special Purpose Acquisition Company. Access official press releases, merger disclosures, and regulatory filings in one centralized location designed for efficient tracking of corporate developments.
This resource delivers timely updates on HLXB's progress toward identifying and executing a business combination. Users will find essential documents including SEC filings, investor communications, and strategic announcements related to the SPAC's acquisition process.
The curated news collection focuses on three key areas: merger/acquisition status updates, leadership team communications, and financial structuring developments. All content is verified through primary sources to ensure compliance with financial disclosure regulations.
Bookmark this page for streamlined access to HLXB's evolving corporate narrative. Check regularly for updates during critical phases of the SPAC lifecycle, particularly as the company approaches its merger deadline.
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II (HLXB) have announced a business combination agreement to create a publicly listed biotechnology company. The transaction, expected to complete in Q3 2025, will provide total proceeds of $450 million, combining HLXB's trust account funds and a $260 million PIPE financing led by Cormorant Asset Management.
The combined entity will focus on developing therapies for RAS and PI3Kα malignancies through three lead programs:
- BBO-8520: A KRASG12C inhibitor in Phase 1 trials for non-small cell lung cancer
- BBO-10203: An oral small molecule in Phase 1 trials for various cancers
- BBO-11818: A pan-KRAS inhibitor expected to begin patient dosing in H1 2025
The combined company is projected to have an implied pro forma equity value of $949 million at closing, assuming a $10.36 share price and no redemptions. BBOT shareholders will roll 100% of their equity into the combined company.
FAQ
What is the current stock price of Helix Acqsn II (HLXB)?
What is the market cap of Helix Acqsn II (HLXB)?
